Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helmut Butzkueven

Showing results (201-210 of 390) with videos related to

Pageof 39
Sort By:
Human Genetics|January 13, 2006
On the utility of data from the International HapMap Project for Australian association studiesJim Stankovich, Charles J Cox, Rachel B Tan, et al.
Scientific Reports|December 18, 2020
Epigenetic differences at the HTR2A locus in progressive multiple sclerosis patientsVicki E Maltby, Rodney A Lea, Sean Burnard, et al.
Multiple Sclerosis and Related Disorders|February 6, 2023
Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activityTim Spelman, Dana Horakova, Serkan Ozakbas, et al.
Multiple Sclerosis and Related Disorders|November 29, 2017
Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimodYara Dadalti Fragoso, Tim Spelman, Cavit Boz, et al.
Muscle & Nerve|June 5, 2025
MGBase: A Global, Observational Registry for Collaborative Research in Myasthenia GravisKatherine A Buzzard, Anneke Van der Walt, Helmut Butzkueven, et al.
Multiple Sclerosis and Related Disorders|May 30, 2018
Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)]Yara Dadalti Fragoso, Tim Spelman, Cavit Boz, et al.
Therapeutic Advances in Neurological Disorders|May 5, 2021
High rates of JCV seroconversion in a large international cohort of natalizumab-treated patientsChristopher M Dwyer, Vilija G Jokubaitis, Jim Stankovich, et al.
Acta Neuropathologica|April 29, 2019
Vitamin D increases glucocorticoid efficacy via inhibition of mTORC1 in experimental models of multiple sclerosisRobert Hoepner, Maud Bagnoud, Maximilian Pistor, et al.
Novartis Foundation Symposium|July 8, 2005
Multiple sclerosis: a haplotype association studySimon J Foote, Justin P Rubio, Melanie Bahlo, et al.
Neurology|February 2, 2024
Risk of Cervical Abnormalities for Women With Multiple Sclerosis Treated With Moderate-Efficacy and High-Efficacy Disease-Modifying TherapiesFrancesca Bridge, Julia Brotherton, Jim Stankovich, et al.
Pageof 39

Showing results (201-210 of 390) with videos related to

Sort By:
Pageof 39
Human Genetics|January 13, 2006
On the utility of data from the International HapMap Project for Australian association studiesJim Stankovich, Charles J Cox, Rachel B Tan, et al.
Scientific Reports|December 18, 2020
Epigenetic differences at the HTR2A locus in progressive multiple sclerosis patientsVicki E Maltby, Rodney A Lea, Sean Burnard, et al.
Multiple Sclerosis and Related Disorders|February 6, 2023
Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activityTim Spelman, Dana Horakova, Serkan Ozakbas, et al.
Multiple Sclerosis and Related Disorders|November 29, 2017
Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimodYara Dadalti Fragoso, Tim Spelman, Cavit Boz, et al.
Muscle & Nerve|June 5, 2025
MGBase: A Global, Observational Registry for Collaborative Research in Myasthenia GravisKatherine A Buzzard, Anneke Van der Walt, Helmut Butzkueven, et al.
Multiple Sclerosis and Related Disorders|May 30, 2018
Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)]Yara Dadalti Fragoso, Tim Spelman, Cavit Boz, et al.
Therapeutic Advances in Neurological Disorders|May 5, 2021
High rates of JCV seroconversion in a large international cohort of natalizumab-treated patientsChristopher M Dwyer, Vilija G Jokubaitis, Jim Stankovich, et al.
Acta Neuropathologica|April 29, 2019
Vitamin D increases glucocorticoid efficacy via inhibition of mTORC1 in experimental models of multiple sclerosisRobert Hoepner, Maud Bagnoud, Maximilian Pistor, et al.
Novartis Foundation Symposium|July 8, 2005
Multiple sclerosis: a haplotype association studySimon J Foote, Justin P Rubio, Melanie Bahlo, et al.
Neurology|February 2, 2024
Risk of Cervical Abnormalities for Women With Multiple Sclerosis Treated With Moderate-Efficacy and High-Efficacy Disease-Modifying TherapiesFrancesca Bridge, Julia Brotherton, Jim Stankovich, et al.
Pageof 39